Entasis Therapeutics Holdings Overview

Entasis Therapeutics Holdings Research & Development

Research & Development expenses for ETTX.

Quarterly R&D Expenses

$10.99M

↑ 17.31% YoY

As of Mar 31, 2022

Annual R&D Expenses (TTM)

$67.36M

↑ 73.76% YoY

Trailing 12 months ending Mar 31, 2022

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin